Verheul HMW - Search Results

1

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer.

Iyer KK, van Erp NP, Tauriello DVF, Verheul HMW, Poel D. Iyer KK, et al. Among authors: verheul hmw. Cancer Treat Rev. 2022 Nov;110:102466. doi: 10.1016/j.ctrv.2022.102466. Epub 2022 Sep 21. Cancer Treat Rev. 2022. PMID: 36183569 Free article. Review.

2

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Gotink KJ, Verheul HM. Gotink KJ, et al. Angiogenesis. 2010 Mar;13(1):1-14. doi: 10.1007/s10456-009-9160-6. Epub 2009 Dec 11. Angiogenesis. 2010. PMID: 20012482 Free PMC article. Review.

3

Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.

Westgeest HM, van Erp NP, Honeywell RJ, Hoekstra R, Peters GJ, Verheul HM. Westgeest HM, et al. J Clin Oncol. 2013 Feb 20;31(6):e83-6. doi: 10.1200/JCO.2012.43.6485. Epub 2012 Nov 26. J Clin Oncol. 2013. PMID: 23182994 No abstract available.

4

Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.

de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H. de Wit D, et al. Ther Drug Monit. 2015 Jun;37(3):331-8. doi: 10.1097/FTD.0000000000000141. Ther Drug Monit. 2015. PMID: 25271729 Clinical Trial.

5

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.

Gotink KJ, Rovithi M, de Haas RR, Honeywell RJ, Dekker H, Poel D, Azijli K, Peters GJ, Broxterman HJ, Verheul HM. Gotink KJ, et al. Cell Oncol (Dordr). 2015 Apr;38(2):119-29. doi: 10.1007/s13402-015-0218-8. Epub 2015 Feb 11. Cell Oncol (Dordr). 2015. PMID: 25665527 Free PMC article.

6

Dried blood spot analysis for therapeutic drug monitoring of pazopanib.

de Wit D, den Hartigh J, Gelderblom H, Qian Y, den Hollander M, Verheul H, Guchelaar HJ, van Erp NP. de Wit D, et al. J Clin Pharmacol. 2015 Dec;55(12):1344-50. doi: 10.1002/jcph.558. Epub 2015 Jul 14. J Clin Pharmacol. 2015. PMID: 26032288 Clinical Trial.

7

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.

Rovithi M, de Haas RR, Honeywell RJ, Poel D, Peters GJ, Griffioen AW, Verheul HM. Rovithi M, et al. J Exp Clin Cancer Res. 2016 Sep 7;35(1):138. doi: 10.1186/s13046-016-0411-2. J Exp Clin Cancer Res. 2016. PMID: 27604186 Free PMC article.

8

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.

Labots M, Gotink KJ, Dekker H, Azijli K, van der Mijn JC, Huijts CM, Piersma SR, Jiménez CR, Verheul HM. Labots M, et al. Exp Mol Med. 2016 Dec 16;48(12):e279. doi: 10.1038/emm.2016.114. Exp Mol Med. 2016. PMID: 27980342 Free PMC article.

9

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.

van Helden EJ, Menke-van der Houven van Oordt CW, Heymans MW, Ket JCF, van den Oord R, Verheul HMW. van Helden EJ, et al. Among authors: verheul hmw. Cancer Metastasis Rev. 2017 Jun;36(2):395-406. doi: 10.1007/s10555-017-9668-y. Cancer Metastasis Rev. 2017. PMID: 28695301 Free PMC article. Review.

10

Insight in taste alterations during treatment with protein kinase inhibitors.

van der Werf A, Rovithi M, Langius JAE, de van der Schueren MAE, Verheul HMW. van der Werf A, et al. Among authors: verheul hmw. Eur J Cancer. 2017 Nov;86:125-134. doi: 10.1016/j.ejca.2017.09.006. Epub 2017 Oct 4. Eur J Cancer. 2017. PMID: 28987769 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters